Ergo Science Incorporated
12Patents
0Active
12Granted
32Portfolio score
Filing activity: Jun 24, 1991 → Oct 31, 1995
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5714519A | Method for regulating glucose metabolism | Human Necessities | 76 | Expired |
| US5344832A | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates | Human Necessities | 63 | Expired |
| US5679685A | Accelerated release composition containing bromocriptine | Human Necessities | 58 | Expired |
| US5585347A | Methods for the determination and adjustment of prolactin daily rhythms | Emerging Cross-Sectional Technologies | 43 | Expired |
| US5626860A | Method for regulating metabolism with dopamine beta hydroxylase inhibitors | Human Necessities | 41 | Expired |
| US5554623A | Method for the long term reduction of body fat stores, insulin resistance, hypersinsulinemia and hyperglycemia in vertebrates | Human Necessities | 40 | Expired |
| US5905083A | Method of treating rheumatoid arthritis | Human Necessities | 38 | Expired |
| US5565454A | Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions | Human Necessities | 32 | Expired |
| US5635512A | Method for modifying or resetting the prolactin rhythm of an insulin insensitive or diabetic animal or human | Human Necessities | 30 | Expired |
| US5688794A | Method for modifying or regulating lipid metalolism in an animal or human subject with a proclactin stimulating compound | Emerging Cross-Sectional Technologies | 30 | Expired |
| US5700800A | Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound | Human Necessities | 29 | Expired |
| US5654313A | Method for modifying or regulating the glucose metabolism of an animal or human subject | Human Necessities | 29 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.